Where nanoengineering meets drug formulation

By Kevin Robinson | Published: 10-Jun-2026
Research & Development

How Nanexa is turning short-acting drugs into long-acting injectables

You need to be a subscriber to read this article.
Click here to find out more.

PharmaShell by Nanexa is an innovative drug delivery system that uses nanometre-thin inorganic coatings to turn short-acting drugs into long-acting injectables.

By enabling a steady, extended release of medication from a single treatment, PharmaShell can dramatically reduce dosing frequency and improve efficacy.

The atomic layer deposition (ALD) platform encapsulates active pharmaceutical ingredients (APIs) in an inorganic coating.

The coating is applied one atomic layer at a time and release profiles can be tailored by adjusting parameters such as composition and thickness.

From cost-effective and scalable manufacturing to patient-centricity benefits, the technology offers many advantages. Dr Kevin Robinson (KSR) spoke to CEO David Westberg (DW) to find out more. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

PhoreMost announces PMC-001 as lead oncology programme

Read more
The biotech will advance the small molecule towards Phase I trials, positioning it for the treatment of primary and secondary brain cancers. Dr Gabriel Fox will also join the company as Consulting Chief Medical Officer to lead the clinical development of the molecule

Trending Articles

  1. The IND advantage: why early derisking is a strategic imperative for complex biologics As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
  2. AI-designed drug product enters clinical development Phase I study of an AI-designed oral formulation sets a new standard in drug development
  3. Cutting-edge wiped film evaporator installation – non-tobacco nicotine products Successful system installation for a UK research and development facility developing and commercialising non-tobacco nicotine products using industry-leading evaporation equipment
  4. Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
  5. Why integrated outsourcing wins in modern drug development Aligning drug substance and drug product development within a single outsourcing model accelerates timelines, sharpens CMC decisions and reduces risk by enabling parallel workstreams and shared governance

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

PhoreMost announces PMC-001 as lead oncology programme

The biotech will advance the small molecule towards Phase I trials, positioning it for the treatment of primary and secondary brain cancers. Dr Gabriel Fox will also join the company as Consulting Chief Medical Officer to lead the clinical development of the molecule
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development

Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation

New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Manufacturing

Cutting-edge wiped film evaporator installation – non-tobacco nicotine products

Successful system installation for a UK research and development facility developing and commercialising non-tobacco nicotine products using industry-leading evaporation equipment
Manufacturing

Why integrated outsourcing wins in modern drug development

Aligning drug substance and drug product development within a single outsourcing model accelerates timelines, sharpens CMC decisions and reduces risk by enabling parallel workstreams and shared governance
Subscribe now